An observational study in Obstructive Sleep Apnea, sponsored by ResMed. Not yet recruiting at 5 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-19.
Sponsored by ResMed · Observational
Among 50 studies in Sleep Apnea, Obstructive by ResMed — 9 open to participants now, 10 under way, none of them phase 3. Sleep Apnea, Obstructive · ResMed.
Among the 50 studies in Sleep Apnea, Obstructive by ResMed, this one is one of 4 that started in 2026, is the only one of another kind, and was the 48th registered.
2,240 studies on the registry are indexed under Sleep Apnea, Obstructive; 475 are open to participants now.
This study's planned enrollment of 90 is below the median of 105 across 666 observational studies indexed under Sleep Apnea, Obstructive.
Browse Sleep Apnea, Obstructive studies →9 of the 50 studies in Sleep Apnea, Obstructive by ResMed are open now, in 1 country. Each count lists the studies.
Of the 313 Sleep Apnea, Obstructive studies recruiting now, 145 (46%) set no upper age limit and 125 (40%) stop at 75 or younger; 53 take children under 18; 65 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →50 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 4 started in 2026.
Median enrollment 30 across the 42 interventional studies, 430 across the 8 observational. Of the 38 that completed or were terminated, 15 (39%) have results posted.
ResMed is the lead sponsor of 105 studies on the registry; 13 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 6 (50%) have results posted.
5 of the studies in Sleep Apnea, Obstructive by ResMed that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07564310ResMedINFORMing Patients With Oximetry Data to Improve MAD Engagement | 2026-12-01 |
| NCT07400861ResMedStudy of Min-Max APAP Recommender Tool | 2026-12-01 |
| NCT06930404ResMedData Collection Study to Review Novel Methods for Diagnosing Obstructive Sleep Apnea | 2026-12-30 |
| NCT05262439ResMedPost Market Clinical Follow up of ResMed Mask Systems | 2027-06 |
| NCT07785310ResMedPAP-NAP Device Clinical Study | 2027-09-01 |
Among the 50 studies in Sleep Apnea, Obstructive by ResMed, from their registry updates:
Nothing recorded among them since 2026-09-25.
Resmed is the manufacturer of medical devices which screen, diagnose, treat and monitor people with sleeping and respiratory disorders, such as obstructive sleep apnea (OSA).
From time to time, for regulatory, quality, and marketing purposes, there may be a need to test the various products performance against PSG (gold standard technology), and other products.
The purpose of this study is:
Patient suspected or known to have OSA
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Suspected of obstructive sleep apnea and about to undergo assessment
Device: Device A · Device: Device B · Device: Device C · Device: Device D · Device: Device E · Diagnostic Test: Screener A
A finger worn OSA home sleep test (HST) diagnostic device
A wrist worn OSA home sleep test (HST) diagnostic device
Ring: wellness device
Torso and limb worn patches
An eye mask
A mobile app screener
Sensitivity
Sensitivity is defined as the device's ability to correctly diagnose patients with OSA, relative to AHI 5
Time frame: Single night PSG
Specificity
Specificity is defined as the device's ability to correctly identify patients without OSA, relative to AHI 5.
Time frame: A single night PSG
Severity Categorisation
Ability to correctly identify OSA severity category, based on AHI threshold values (normal, mild, moderate, severe).
Time frame: A single night PSG
Total Sleep Time
Total portion of the recording identified as sleep time
Time frame: A single night PSG
ODI
The Oxygen Desaturation Index (ODI) measures the number of times per hour of sleep that blood oxygen levels drop by a specific percentage from baseline
Time frame: A single night PSG
Sleep Staging
Time in the various sleep stages, Stage 1 (light sleep), Stage 2 (deeper, intermediate), Stage 3 (deep, slow-wave sleep/restorative) and REM.
Time frame: A single night PSG
Plan to share: No
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.